Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress

On April 25, 2023 Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, reported that it will discuss the potential of using epigenetic reprogramming to fight disease, including cancer (Press release, Turn Biotechnologies, APR 25, 2023, View Source [SID1234630498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mustafa Turkoz, PhD, Turn Bio immunology, will share data showing the company has used its ERA (Epigenetic Reprogramming of Age) technology to enhance T cell performance against tumor cells. The technology is expected to improve the efficacy of CAR-T cell therapies.

Turn Biotechnologies has used its ERA (Epigenetic Reprogramming of Age) technology to enhance T cell performance against tumor cells. The technology is expected to improve the efficacy of CAR-T cell therapies. Data will be shared at the World Oncology Cell Therapy Congress on Wednesday.

The discussion will occur at the World Oncology Cell Therapy Congress being held April 25-26 in Boston.

Presentation details:

Title: "Restoring youthful vigor to cells to fight disease through epigenome reprogramming."
Location: Hyatt Regency Boston, One Avenue De Lafayette, Boston, during the Developing Better TCR-Directed Approaches.

Date and Time: Wednesday, April 26, 2023, at 3 p.m. Eastern Time.
The World Oncology Cell Therapy Congress is the only annual meeting that brings together drug developers, solution providers, and clinicians whose purpose is to deliver safe and effective adoptive cell therapy products to clinical implementation. The meeting is expected to attract hundreds of participants.

HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)

On April 26, 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) reported that it has developed a HER2-targeted DEP SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu[2] (Press release, Starpharma, APR 25, 2023, View Source;mc_eid=bf52dd3418 [SID1234630497]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ADCs represent an innovative and growing area of cancer treatment, with encouraging clinical advances and product approvals in recent years. The global ADC market grew from USD ~$5.8 billion in 2021 to USD ~$8.0 billion in 2022 and is projected to reach USD ~$22.9 billion in 2030[3]. HER2 is an important target for cancer treatments, with ADCs targeting this receptor showing significant promise. Currently marketed HER2-targeted ADCs include Kadcyla (Genentech and Roche) and Enhertu (AstraZeneca and Daiichi-Sankyo), which is now approved for use in patients with HER2+ or HER2-low metastatic breast cancer, HER2+ metastatic gastric or gastroesophageal junction cancer, and HER2-mutant metastatic non-small-cell lung cancer[4].

Starpharma’s HER2-targeted DEP SN-38 ADC comprises a HER2-directed antibody, trastuzumab, linked to DEP dendrimers loaded with the topoisomerase I inhibitor, SN-38, which is the active metabolite of irinotecan. Starpharma’s HER2-targeted DEP SN-38 ADC has been designed with a higher drug-to-antibody ratio (DAR), or drug loading, than currently marketed ADCs.

The anti-cancer activity of Starpharma’s HER2-targeted DEP SN-38 ADC was demonstrated in an established HER2+ human cancer xenograft model, utilising the SKOV-3 ovarian cancer cell line that overexpresses HER2. The HER2-targeted DEP SN-38 ADC and Enhertu, dosed intravenously (IV) on study days 1, 8 and 15, significantly inhibited tumour growth compared with saline control. The anti-tumour effect of the HER2-targeted DEP SN-38 ADC was statistically significantly greater than the anti-tumour effect of Enhertu over the duration of the study (p<0.0001). All animals in the HER2-targeted DEP SN-38 ADC group survived to the end-of-study and survival was statistically significantly greater for the HER2-targeted DEP SN-38 ADC-treated animals compared with Enhertu and the saline control group (p<0.0002).

Starpharma’s HER2-targeted DEP SN-38 ADC, containing SN-38, achieved superior tumour growth inhibition and survival compared with Enhertu, despite the active drug in Enhertu, DXd, being approximately 10 times more potent against topoisomerase I than SN-38[5].

Key advantages of Starpharma’s DEP platform for ADCs include its ability to achieve higher DAR, and therefore higher drug payload, than conventional ADCs (see Table 1, below); its greater flexibility in terms of linker strategies to precisely control drug release profiles; and its ability to widen the therapeutic index of toxic drug payloads. In addition, Starpharma’s DEP platform provides unique flexibility in terms of compatible targeting agents, including biologics (whole antibodies and fragments), small molecules, peptides and other approaches.

Table 1. HER2 ADCs Drug-to-Antibody Ratios (DAR), Drug Payload and Payload Mechanism of Action

HER2 ADC

Approximate Drug-to-Antibody Ratio (DAR)

Drug Payload

Payload Mechanism of Action

Kadcyla

(Genentech/Roche)

3.5

DM-1 (emtansine)

Microtubule

inhibitor

Enhertu

(AstraZeneca/Daiichi-Sankyo)

8

DXd (exatecan derivative)

Topoisomerase I inhibitor

HER2-targeted DEP

SN-38 ADC

(Starpharma)

13

SN-38

Topoisomerase I inhibitor

Starpharma CEO, Dr Jackie Fairley, said: "Antibody-drug conjugates are one of the fastest growing classes of anti-cancer drugs, with significant progress being made in recent years, including the recent approval and clinical success of Enhertu, which has shown significant promise in helping patients with HER2+ cancers.

"Starpharma is pleased to report this new data for its internally developed HER2-targeted DEP SN-38 ADC demonstrating significant anti-tumour activity and survival, compared to Enhertu, in a HER2+ cancer model.

"Starpharma’s DEP technology delivers a number of advantages in the design of innovative ADCs, including the ability to load more drug payload molecules per construct and having greater flexibility in linker strategies. In addition to our internal activities in this area, Starpharma is delighted to be working in partnership with a number of companies, including MSD, to develop dendrimer-based ADCs using Starpharma’s DEP technology."

Study Methods

Starpharma evaluated the anti-cancer activity of HER2-targeted DEP SN-38 ADC compared to Enhertu in an established HER2+ human cancer xenograft model. The study was conducted at the Monash Institute of Pharmaceutical Sciences (MIPS).

This murine xenograft study used the HER2+ SKOV-3 ovarian cancer cell line, in NOD-SCID-Gamma (NSG) immunodeficient mice. The SKOV-3 cell line was chosen because it naturally overexpresses HER2 and is not dependent on estrogen for growth and survival, meaning that it is a robust model for evaluation of HER2-targeting drugs. Tumour cells were inoculated subcutaneously and the resultant tumours were measured 2-3 times weekly using electronic calipers. Tumour volume (mm3) was calculated at each timepoint.

Following tumour establishment, groups of mice (n = 7-8 per group) were dosed IV on days 1, 8, and 15 as follows:

Vehicle (saline)
Control dendrimer-SN-38[6] – 3.28 mg/kg (SN-38 equivalent)
Enhertu – 5 mg/kg (total construct dose)[7]
HER2-targeted DEP SN-38 ADC – 3.28 mg/kg (SN-38 equivalent)
Study Results

Effect of HER2-targeted DEP SN-38 ADC vs. Enhertu on Tumour Volume Over Time

Figure 1. HER2-targeted DEP SN-38 ADC achieved statistically significantly enhanced tumour growth inhibition compared with Enhertu or the control dendrimer that lacked the HER2-targeting antibody (p<0.0001 for both comparisons). Points and error bars show means ± standard error of the mean (SEM). Statistical analyses used the Mixed Effects Model (GraphPad Prism v9.4.1).

Kaplan-Meier Survival Curve

Figure 2. Analysis of survival curves showed significantly enhanced probability of survival of the HER2-targeted DEP SN-38 ADC group versus all other groups (p<0.0002). Probability of survival in the HER2-targeted DEP SN-38 ADC group was 100% (at end-of-study, 45 days). Median survival, or the time at which probability of survival dropped to 50%, was 40 days for Enhertu, 28 days for the control dendrimer, and 13 days for the vehicle control. Survival analyses used tumour volume (≥ 1000 mm3), tumour-site ulceration, or end-of-study as endpoints.

Survival analyses used the logrank (Mantel-Cox) test (GraphPad Prism v9.4.1).

All treatments were well tolerated, as measured by change in body weight over time.

[1] Human epidermal growth factor receptor 2

[2] ENHERTU is a registered trademark of Daiichi Sankyo Company Limited. Enhertu comprises the humanised monoclonal antibody/HER2-directed antibody, trastuzumab, covalently linked to a topoisomerase I inhibitor payload, DXd (an exatecan derivative)

[3] View Source

[4] View Source

[5] Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097-5108. doi:10.1158/1078-0432.CCR-15-2822

[6] Control dendrimer-SN-38 = DEP dendrimer with SN-38 covalently attached (the same dendrimer and linker used to make DEP SN-38 ADC but lacking the HER2 targeting moiety, i.e., trastuzumab).

[7] In preclinical studies, Enhertu has been used at doses ranging from 3-10 mg/kg IV. The area under the curve (AUC) in mice at 5 mg/kg Enhertu is estimated to be comparable with that of Enhertu in humans at the clinical dosage, and hence 5 mg/kg was selected as the dose for the current study.

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

On April 25, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will report its financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023 (Press release, Mirati, APR 25, 2023, View Source [SID1234630496]). During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 8109078. A replay of the call will be available approximately 2 hours after the event has ended at the same website.

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

On April 25, 2023 Exelixis, Inc. (Nasdaq: EXEL) reported that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close (Press release, Exelixis, APR 25, 2023, View Source [SID1234630495]). At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS

On April 25, 2023 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment for cancer and fibrosis, reported further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 31 March 2023 (Press release, Amplia Therapeutics, APR 25, 2023, View Source;[email protected] [SID1234630494]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Highlights from the Quarter
• Review of available data from patients in Cohort 1 of the ACCENT trial of AMP945 in
pancreatic cancer, concluded that dose escalation to a further cohort was appropriate
• Recruitment of three patients into Cohort 2 of the ACCENT trial
• Presentations of data from preclinical and clinical studies of AMP945 in pancreatic cancer presented at two high-profile cancer conferences

Operations Update

Clinical Development

Amplia’s primary focus is progression of the Phase 1b/2a ACCENT clinical trial. This trial tests whether our best-in-class focal adhesion kinase inhibitor AMP945 enhances the efficacy of standard-of-care gemcitabine/nab-paclitaxel chemotherapy in frontline patients with advanced pancreatic cancer (see ClinicalTrials.gov under the identifier NCT05355298). The trial is recruiting patients at seven sites in Melbourne, Sydney and, most recently, Brisbane, and the rate of patient recruitment is meeting expectations. Opening of the Brisbane site at Greenslopes Medical Centre received considerable media attention increasing our ability to recruit patients into the trial. We have also made progress on a regulatory submission to South Korea which, if approved, will allow sites to be opened in that country that should further enhance recruitment rate in the Phase 2a portion of the trial.

During the Quarter, Amplia announced that review of available safety, pharmacokinetic and pharmacodynamic data from patients in Cohort 1 of the Phase 1b portion of the trial indicated that dose-escalation to a second patient cohort was warranted. Importantly, this second cohort of patients was recruited during the quarter. The clinical trial continues.

Non-clinical Development

Preclinical studies of AMP945, along with AMP886, Amplia’s second FAK inhibitor, are being undertaken with academic collaborators and contract research organizations to explore additional clinical potential for these drugs in cancer and fibrotic diseases. Results from some of these preclinical studies have been recently presented at separate top-tier cancer conferences, one in Australia and one in the US, to help raise the profile of the Amplia assets amongst researchers, clinicians and potential partners. A strategy day with the Board, key scientific advisers and Amplia staff, held during the quarter helped refine our preclinical plans, and data from these additional studies will be reported in due course.

Financial update

Amplia finished the March 2023 quarter with cash of $9.3 million (December 2022: $10.6 million).

During the quarter, the Company had net cash outflows of $1.3 million in relation to operating activities (December 2022: $1.1 million). Operating cashflows included outflows and inflows of:

• $0.7 million for staff and administration/corporate costs; and
• $0.7 million for research and development costs, which primarily related to Contract Research Organisation (CRO), manufacturing and other Chemistry, Manufacturing and Control (CMC) related costs incurred in relation to the first stage of the Phase 2 clinical trial for AMP945.

Research and development expenditure is forecast to increase in the coming quarters in line with the progression of Phase 1b/2a of the ACCENT clinical trial for AMP945.

Payments to Related Entities
In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors’ fees, salaries and superannuation. Total payments made for the quarter equals $147,500 and relate to payments to the CEO/Managing Director
in line with employment contracts and payments to the Non-Executive Directors.

Outlook and future activities

Over the coming quarter, the Company expects to report further progress in the ACCENT trial as we finalise dose selection for the Phase 2 portion of the trial. Further progress on the regulatory submission to South Korea will also be reported.

Preclinical studies with AMP945 in additional cancer and non-cancer indications are underway to identify further clinical and commercial opportunities for the drug. Preclinical studies of Amplia’s
second FAK inhibitor, AMP886, are ongoing to identify optimal development pathways for this compound. Data generated from these studies will be communicated as they are received.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.